

Notice on the Establishment of Subsidiary in India

August 2, 2011, Osaka, Japan -- Santen Pharmaceutical Co., Ltd. announced that it has established its subsidiary, Santen India Private Limited (hereafter "Santen India") in India on July 29, 2011 (local time).

India, with the world's second largest population of approximately 1.2 billion, has shown strong economic growth in the recent years, and is expected to sustain such high growth in the foreseeable future. The Indian pharmaceutical market is also expected to expand drastically due to the improvement in medical infrastructure along with increase of patients' awareness and increase of average income.

Santen has been accelerating its business activities not only in Japan, but also in high-growth markets in Europe and Asia to realize the long term strategic vision as "Specialized Pharmaceutical Company with a Global Presence" by 2020. In line with the long term vision, Santen has decided to establish a local entity in India, in order to spread the "Santen" brand with a view to establish its presence in the Indian ophthalmic market. In the initial stage, however, we will mainly focus on exploring business opportunities including product development and production areas.

Profile of the new subsidiary in India

Registered company name:	Santen India Private Limited
Date of incorporation:	July 29, 2011
Location:	Bangalore, Karnataka, India
Paid-in capital:	Rupee 48.5 million (approx. JPY 87.0 million)
Equity ownership:	99.9% by Santen Pharmaceutical Co., Ltd. 0.1% by Santen Holdings U.S. Inc.
Managing director:	Junji Kubo (Subject to the resolution by the Board of Directors at Santen India)

###